20.97

0.52% -0.11

Pre-market: 20.90 -0.07 -0.33%

Castle Biosciences Inc (CSTL)

Overview News Price History Option Chain Financials Why CSTL Down? Discussions Forecast

Castle Biosciences Inc stock is traded at $20.97, with a volume of 312.02K. It is down -0.52% in the last 24 hours and down -15.48% over the past month. Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

Previous Close:

$21.08

Open:

$20.98

24h Volume:

312.02K

Relative Volume:

0.79

Market Cap:

$636.02M

Revenue:

$344.23M

Net Income/Loss:

$-24.16M

P/E Ratio:

-24.76

EPS:

-0.8471

Net Cash Flow:

$28.33M

1W Performance:

+4.07%

1M Performance:

-15.48%

6M Performance:

-46.40%

1Y Performance:

+31.31%

1-Day Range:

$20.45

$21.21

1-Week Range:

$19.55

$22.18

52-Week Range:

$14.59

$44.28

Castle Biosciences Inc Stock (CSTL) Company Profile

Name

Castle Biosciences Inc

Sector

Healthcare (1110)

Industry

Diagnostics & Research (52)

Phone

866-788-9007

Address

1500 W. PARKWOOD AVE., FRIENDSWOOD, TX

Employee

942

Twitter

@castlebio

Next Earnings Date

2026-05-06

Latest SEC Filings

CSTL's Discussions on Twitter

Compare CSTL vs TMO, DHR, IDXX, A, WAT

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CSTL Castle Biosciences Inc	20.97	639.36M	344.23M	-24.16M	28.33M	-0.8471
TMO Thermo Fisher Scientific Inc	494.04	183.03B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	179.87	129.29B	24.78B	3.68B	5.29B	5.1743
IDXX Idexx Laboratories Inc	566.79	44.45B	4.45B	1.10B	1.06B	13.59
A Agilent Technologies Inc	135.98	38.25B	7.23B	1.41B	1.09B	4.979
WAT Waters Corp	378.16	37.66B	3.77B	449.25M	240.68M	7.8556

Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-14-23	Initiated	Guggenheim	Buy
Jan-05-23	Initiated	Scotiabank	Sector Outperform
Jan-07-22	Initiated	Stephens	Overweight
Apr-30-21	Initiated	Lake Street	Buy
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight
Dec-27-19	Reiterated	Canaccord Genuity	Buy
Aug-19-19	Initiated	BTIG Research	Buy
Aug-19-19	Initiated	Canaccord Genuity	Buy
Aug-19-19	Initiated	Robert W. Baird	Outperform
Aug-19-19	Initiated	SVB Leerink	Outperform

View All

Castle Biosciences Inc Stock (CSTL) Latest News

Jun 01, 2026

Maetzold-related trusts sell shares (CSTL) in multiple Form 144 trades - Stock Titan

Jun 01, 2026

Castle Biosciences (CSTL) director receives 11,766 RSUs in new equity grant - Stock Titan

Jun 01, 2026

Director at Castle Biosciences (CSTL) awarded 11,766 restricted stock units - Stock Titan

Jun 01, 2026

Director at Castle Biosciences (CSTL) granted 11,766 RSUs - Stock Titan

Jun 01, 2026

Castle Biosciences (CSTL) director receives 11,766 RSU compensation award - Stock Titan

Jun 01, 2026

Director at Castle Biosciences (CSTL) receives 11,766 RSU equity award - Stock Titan

Jun 01, 2026

Castle Biosciences (NASDAQ: CSTL) grants 11,766 RSUs to director - Stock Titan

Jun 01, 2026

May 29, 2026

Is Castle Biosciences Inc (CSTL) a Bargain After 4.7% Drop? GF V - GuruFocus

May 29, 2026

Castle Biosciences (NASDAQ: CSTL) investors approve directors, pay and KPMG - Stock Titan

May 29, 2026

May 28, 2026

Castle Biosciences (NASDAQ:CSTL) Downgraded by Zacks Research to "Hold" - MarketBeat

May 28, 2026

May 27, 2026

Wall Street analysts predict an 85.15% upside in Castle Biosciences (CSTL): Here's what you should know - MSN

May 27, 2026

Castle Biosciences (CSTL) director receives 13,667 shares via RSUs - Stock Titan

May 27, 2026

Director Daniel Bradbury adds 13,667 CSTL shares via RSU exercise, boosts direct and trust holdings - Stock Titan

May 27, 2026

Castle Biosciences (CSTL) director converts 13,667 RSUs into common shares - Stock Titan

May 27, 2026

Director at Castle Biosciences (CSTL) settles 13,667 RSUs into common stock - Stock Titan

May 27, 2026

Director at Castle Biosciences (NASDAQ: CSTL) converts 13,667 RSUs to shares - Stock Titan

May 27, 2026

Director at Castle Biosciences (CSTL) gains 13,667 shares via RSU exercise - Stock Titan

May 27, 2026

Castle Biosciences (CSTL) director converts 13,667 RSUs into Common Stock - Stock Titan

May 27, 2026

May 26, 2026

Castle Biosciences (CSTL) CCO exercises options to add 11,210 shares - Stock Titan

May 26, 2026

May 24, 2026

How The Castle Biosciences (CSTL) Story Is Shifting After Solid Q1 And Lower Targets - Yahoo Finance

May 24, 2026

May 23, 2026

(CSTL) Volatility Zones as Tactical Triggers - Stock Traders Daily

May 23, 2026

May 22, 2026

Castle Biosciences (CSTL) CEO reports planned stock sales and option exercises - Stock Titan

May 22, 2026

Castle Biosciences, Inc.Common stock (NQ: CSTL - The Chronicle-Journal

May 22, 2026

May 21, 2026

Castle Biosciences (CSTL) is on the Move, Here's Why the Trend Could be Sustainable - MSN

May 21, 2026